See more : G-NEXT Inc. (4179.T) Income Statement Analysis – Financial Results
Complete financial analysis of Immunome, Inc. (IMNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immunome, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MidCap Financial Investment Corporation (MFIC) Income Statement Analysis – Financial Results
- Kawaden Corporation (6648.T) Income Statement Analysis – Financial Results
- Impulse Fitness Solutions S.A (MLIFS.PA) Income Statement Analysis – Financial Results
- Asia Commercial Holdings Limited (0104.HK) Income Statement Analysis – Financial Results
- Stem Cell Authority, Ltd. (SCAL) Income Statement Analysis – Financial Results
Immunome, Inc. (IMNM)
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 14.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 22.93M | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| Gross Profit | -8.91M | -631.00K | -755.00K | -755.00K | -615.00K | -521.00K |
| Gross Profit Ratio | -63.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.80M | 23.27M | 14.11M | 7.49M | 8.82M | 6.88M |
| General & Administrative | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.66M | 13.63M | 11.09M | 4.78M | 1.53M | 866.00K |
| Other Expenses | 0.00 | 0.00 | 503.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 122.82M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Cost & Expenses | 123.55M | 36.90M | 25.20M | 12.26M | 10.35M | 7.74M |
| Interest Income | 2.72M | 5.00K | 10.00K | 1.00K | 10.00K | 39.00K |
| Interest Expense | 0.00 | 5.00K | 10.00K | 38.00K | 106.00K | 141.00K |
| Depreciation & Amortization | 728.00K | 631.00K | 755.00K | 755.00K | 615.00K | 521.00K |
| EBITDA | -28.27M | -36.27M | -23.95M | -17.04M | -9.72M | -7.18M |
| EBITDA Ratio | -201.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.53M | -36.90M | -25.20M | -12.26M | -10.35M | -7.74M |
| Operating Income Ratio | -781.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.72M | 5.00K | 493.00K | -5.58M | -96.00K | -102.00K |
| Income Before Tax | -106.81M | -36.90M | -24.71M | -17.84M | -10.44M | -7.85M |
| Income Before Tax Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 617.00K | -242.00K | -717.00K | 106.00K | 39.00K |
| Net Income | -106.81M | -37.51M | -24.47M | -17.12M | -10.55M | -7.85M |
| Net Income Ratio | -761.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| EPS Diluted | -5.38 | -3.09 | -2.12 | -1.69 | -1.84 | -7.18 |
| Weighted Avg Shares Out | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
| Weighted Avg Shares Out (Dil) | 19.84M | 12.13M | 11.54M | 10.11M | 5.74M | 1.09M |
Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data
Immunome Inc (NASDAQ: IMNM) shares are trading higher after it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the omicron variant (BA.1) when tested in vivo in hamsters. Additional in vitro testing of a SARS-CoV-2 pseudovirus.
Why Immunome Shares Are Rising
Immunome Inc (NASDAQ: IMNM) shares are trading higher by 19.44% at $3.39 after the company published data demonstrating its COVID-19 antibody cocktail IMM-BCP-01 cleared the omicron variant of SARS-CoV-2 when tested in vivo in hamsters. When tested in hamster models, Immunome...
Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain
Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.
Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus
Immunome Inc IMNM shares rose before falling after reporting results from testing its experimental three-antibody cocktail against live versions of the COVID-19 omicron variant. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
FDA Issues Clinical Hold On Immunome's COVID-19 Antibody Program
Immunome Inc (NASDAQ: IMNM) has received an FDA clinical hold letter in response to its recently submitted IND requesting further information related to the preparation and administration of IMM-BCP-01 at clinical sites. The Company has already initiated the requisite work and expects to...
Immunome (IMNM) Stock: Why The Price Increased
The stock price of Immunome Inc (NASDAQ: IMNM) increased by 12.55% in the most recent trading session. This is why it happened.
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present Preclinical Data on Anti IL-38 at AACR's NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Immunome to Present at the Cantor Global Healthcare Conference
EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Cantor Global Healthcare Conference
Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Clips Is Plunging Today
Life Clips (LCLP) stock is falling on Tuesday following an update from the battery company about its recent business announcements. The post LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Clips Is Plunging Today appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports